Mixture to be used for central nervous system clinical trials.
Cambridge Cognition announced that it has officially launched Aqua, its automated quality assurance solution for central nervous system (CNS) clinical trials. Powered by the company’s winterlight speech and language platform, the solution is the first product of its kind to be available on the market.
“Aqua is an entirely new solution for the clinical trials market providing a level of quality assurance that was not possible before, from a cost or time perspective, with traditional reviews by medical experts,” said Matthew Stork, CEO, Cambridge Cognition. “We acquired Winterlight Labs intending to commercialize their innovative verbal clinical assessments and, by launching Aqua, we have achieved the first of our product goals. We are also really pleased to have already won a client for Aqua as we expect this will provide us with an excellent case study for future sales.”
Reference: Launch of automated quality assurance for clinical trials. Cambridge Cognition. October 24, 2023. Accessed October 25, 2023. https://cambridgecognition.com/launch-of-automated-quality-assurance-for-clinical-trials/
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.